Nanoparticle and targeted systems for cancer therapy.

[1]  Shu Chien,et al.  Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases , 2003 .

[2]  I. Rubinstein,et al.  VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Philip S Low,et al.  Immunotherapy of folate receptor-expressing tumors: review of recent advances and future prospects. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Marek Romanowski,et al.  Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[5]  Ernst Wagner,et al.  Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[6]  T. Choueiri,et al.  An overview of targeted treatments in cancer. , 2003, Clinical therapeutics.

[7]  G. Sledge,et al.  Exploiting the hallmarks of cancer: the future conquest of breast cancer. , 2003, European journal of cancer.

[8]  M. Glennie,et al.  Renaissance of cancer therapeutic antibodies. , 2003, Drug discovery today.

[9]  S. Jain,et al.  A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.

[10]  Sung‐Ho Kim,et al.  Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety. , 2003, International journal of pharmaceutics.

[11]  S. Feng,et al.  A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[12]  S. Simões,et al.  Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[13]  P. Couvreur,et al.  Nanoparticles in cancer therapy and diagnosis. , 2002, Advanced drug delivery reviews.

[14]  Ulrik B Nielsen,et al.  Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. , 2002, Biochimica et biophysica acta.

[15]  M. Bednarski,et al.  Tumor Regression by Targeted Gene Delivery to the Neovasculature , 2002, Science.

[16]  D. Aggarwal,et al.  Paclitaxel and its formulations. , 2002, International journal of pharmaceutics.

[17]  M. Okabe,et al.  Enhanced tumor cell selectivity of adriamycin-monoclonal antibody conjugate via a poly(ethylene glycol)-based cleavable linker. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[18]  A. J. Mixson,et al.  Targeting tumor angiogenesis with gene therapy. , 2001, Molecular genetics and metabolism.

[19]  A. Maitra,et al.  Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[20]  E. Wagner,et al.  Different strategies for formation of pegylated EGF-conjugated PEI/DNA complexes for targeted gene delivery. , 2001, Bioconjugate chemistry.

[21]  S. Feng,et al.  Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[22]  T. Park,et al.  In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[23]  A. Maitra,et al.  Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. , 2000, International journal of pharmaceutics.

[24]  A. Schätzlein,et al.  Tumour vasculature as a target for anticancer therapy. , 2000, Cancer treatment reviews.

[25]  B. Teicher.  Molecular targets and cancer therapeutics: discovery, development and clinical validation. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[26]  J. Marks,et al.  Toward selection of internalizing antibodies from phage libraries. , 1999, Biochemical and biophysical research communications.

[27]  M. Colombo,et al.  IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. , 1998, Cancer research.

[28]  A. Harris,et al.  New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. , 1998, The cancer journal from Scientific American.

[29]  Chari,et al.  Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy. , 1998, Advanced drug delivery reviews.

[30]  T. Luger,et al.  Endothelial cells and angiogenesis , 1997, Experimental dermatology.

[31]  M. Buchberger,et al.  Coupling of cell-binding ligands to polyethylenimine for targeted gene delivery , 1997, Gene Therapy.

[32]  H. Sato,et al.  Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol. , 1996, Chemical & pharmaceutical bulletin.

[33]  Gert Storm,et al.  Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system , 1995 .

[34]  R Bicknell,et al.  Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. , 1993, Cancer research.

[35]  D E Ingber,et al.  Fibronectin controls capillary endothelial cell growth by modulating cell shape. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Folkman.  Successful treatment of an angiogenic disease. , 1989, The New England journal of medicine.

[37]  J. Denekamp,et al.  Endothelial proliferation in tumours and normal tissues: continuous labelling studies. , 1984, British Journal of Cancer.

[38]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[39]  A. Reynolds,et al.  Nanoparticle-mediated gene delivery to tumour neovasculature. , 2003, Trends in Molecular Medicine.

[40]  M. Meng,et al.  Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. , 2002, Urology.

[41]  H. Ichikawa,et al.  In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[42]  R K Jain,et al.  Transport of molecules, particles, and cells in solid tumors. , 1999, Annual review of biomedical engineering.